Roth Capital initiates MediciNova at $6 price target
Roth Capital initiated coverage of MediciNova with a Buy rating and a $6.00 share price target, as cited.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.